These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24053345)

  • 1. Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.
    Watzlawik JO; Wootla B; Painter MM; Warrington AE; Rodriguez M
    Expert Rev Neurother; 2013 Sep; 13(9):1017-29. PubMed ID: 24053345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method of identifying natural antibodies for remyelination.
    Warrington AE; Rodriguez M
    J Clin Immunol; 2010 May; 30 Suppl 1(0 1):S50-5. PubMed ID: 20387101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease.
    Warrington AE; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():213-39. PubMed ID: 18219820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG?
    Warrington AE; Van Keulen V; Pease LR; Rodriguez M
    Adv Exp Med Biol; 2012; 750():44-55. PubMed ID: 22903665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.
    Asakura K; Miller DJ; Pease LR; Rodriguez M
    J Neurosci; 1998 Oct; 18(19):7700-8. PubMed ID: 9742140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-faceted role of naturally occurring autoantibodies in fighting pathogens.
    Bouhlal H; Kaveri S
    Adv Exp Med Biol; 2012; 750():100-13. PubMed ID: 22903669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally occurring IgM antibodies to oxidation-specific epitopes.
    Binder CJ
    Adv Exp Med Biol; 2012; 750():2-13. PubMed ID: 22903662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens.
    Asakura K; Pogulis RJ; Pease LR; Rodriguez M
    J Neuroimmunol; 1996 Mar; 65(1):11-9. PubMed ID: 8642059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma.
    Rosenbluth J; Schiff R; Liang WL; Dou W
    J Neurocytol; 2003 Mar; 32(3):265-76. PubMed ID: 14724389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.
    Wootla B; Watzlawik JO; Denic A; Rodriguez M
    Expert Rev Clin Immunol; 2013 Jun; 9(6):535-49. PubMed ID: 23730884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive human immunity drives remyelination in a mouse model of demyelination.
    El Behi M; Sanson C; Bachelin C; Guillot-Noël L; Fransson J; Stankoff B; Maillart E; Sarrazin N; Guillemot V; Abdi H; Cournu-Rebeix I; Fontaine B; Zujovic V
    Brain; 2017 Apr; 140(4):967-980. PubMed ID: 28334918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invited article: human natural autoantibodies in the treatment of neurologic disease.
    Rodriguez M; Warrington AE; Pease LR
    Neurology; 2009 Apr; 72(14):1269-76. PubMed ID: 19349608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune promotion of central nervous system remyelination.
    Rodriguez M; Miller DJ
    Prog Brain Res; 1994; 103():343-55. PubMed ID: 7886217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgM Natural Autoantibodies in Physiology and the Treatment of Disease.
    Fereidan-Esfahani M; Nayfeh T; Warrington A; Howe CL; Rodriguez M
    Methods Mol Biol; 2019; 1904():53-81. PubMed ID: 30539466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination.
    Pavelko KD; van Engelen BG; Rodriguez M
    J Neurosci; 1998 Apr; 18(7):2498-505. PubMed ID: 9502810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody.
    Grassi S; Cabitta L; Prioni S; Mauri L; Ciampa MG; Yokoyama N; Iwabuchi K; Zorina Y; Prinetti A
    Neurochem Res; 2023 Jun; 48(6):1783-1797. PubMed ID: 36695984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.
    Wootla B; Watzlawik JO; Warrington AE; Wittenberg NJ; Denic A; Xu X; Jordan LR; Papke LM; Zoecklein LJ; Pierce ML; Oh SH; Kantarci OH; Rodriguez M
    JAMA Neurol; 2015 Nov; 72(11):1346-53. PubMed ID: 26389734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated remyelination: relevance to multiple sclerosis.
    Bieber A; Asakura K; Warrington A; Kaveri SV; Rodriguez M
    Mult Scler; 2000 Oct; 6 Suppl 2():S1-5; discussion S33. PubMed ID: 11188771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis.
    Kirschning E; Jensen K; Dübel S; Rutter G; Hohenberg H; Will H
    J Neuroimmunol; 1999 Sep; 99(1):122-30. PubMed ID: 10496185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficient clearance of myelin debris by microglia impairs remyelinating processes.
    Lampron A; Larochelle A; Laflamme N; Préfontaine P; Plante MM; Sánchez MG; Yong VW; Stys PK; Tremblay MÈ; Rivest S
    J Exp Med; 2015 Apr; 212(4):481-95. PubMed ID: 25779633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.